small molecule

XPOVIO

SELINEXOR

Loss of exclusivityAugust 2035latest FDA-listed patent expiry

CompanyKaryopharm Therapeutics →See this company's full patent-cliff portfolio

Drug detail

Brand name	XPOVIO
Active ingredient	SELINEXOR
Strength	40MG
Dosage form	TABLET
Route	ORAL
Modality	Small molecule
FDA approval	April 2021
Marketing status	RX

Listed patents

Patent	Expires	Type
11753401	August 2035	product
10519139	August 2035	substance, product
11746102	August 2035	use U-3018
11807629	August 2035	substance, product
8999996	July 2033	substance, product
9714226	July 2032	substance, product
9079865	July 2032	use U-3018
12291508	July 2032	use U-3018
11787771	July 2032	use U-2584
11034660	July 2032	use U-3018
10544108	July 2032	use U-2584

Regulatory exclusivity

Code	Expires
ODE*	December 2027
ODE*	June 2027
ODE*	July 2026

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

Drug detail

Listed patents

Regulatory exclusivity

More from Karyopharm Therapeutics